Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Blood. 2022 Jan 27;139(4):624-629. doi: 10.1182/blood.2021012589.

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Haemato-Oncology, King's College London, London, United Kingdom.
³ Service d'Hématologie Séniors, Hôpital Saint Louis, Université Paris 7, Paris, France.
⁴ Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
⁵ MDS Unit, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁶ Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain.
⁷ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli" Bologna, Bologna, Italy.
⁸ Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
⁹ Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
¹⁰ Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT.
¹¹ Bristol Myers Squibb, Princeton, NJ.
¹² Acceleron Pharma, Cambridge, MA.
¹³ Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; and.
¹⁴ Moffitt Cancer Center, Tampa, FL.

No abstract available

Publication types